Alembic Pharmaceuticals Secures USFDA Approval for Methotrexate Injection
Alembic Pharmaceuticals Ltd has received final USFDA approval for its methotrexate injection, used to treat various cancers and arthritis. The approval covers multi-dose and single-dose vials, equivalent to Hospira's product. Methotrexate is indicated for neoplastic diseases and severe arthritis conditions, enhancing Alembic's portfolio.
- Country:
- India
Alembic Pharmaceuticals Ltd has announced it secured final approval from the US Food & Drug Administration for its generic methotrexate injection. This injectable treatment is used for multiple cancers and arthritis.
The approval pertains to the abbreviated new drug application for methotrexate injection across various strengths, reflecting its equivalence to Hospira's listed product.
Methotrexate is critically employed in treating conditions like acute lymphoblastic leukemia, osteosarcoma, and rheumatoid arthritis, marking a significant milestone for Alembic's growing product lineup.
Google News